ContraFect Corporation - Company & Market Research Reports

ContraFect Corporation is a biotechnology company that develops therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.